{"gene":"ETS2","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":1996,"finding":"Ras signaling induces phosphorylation of a conserved threonine residue (Thr-72) in ETS2, and mutation of this residue to alanine abrogates Ras-mediated superactivation of Ets-AP-1 reporter genes, establishing Thr-72 phosphorylation as a necessary molecular component of Ras-mediated ETS2 activation.","method":"Transient transfection reporter assays, site-directed mutagenesis, phosphoamino acid analysis of radiolabeled ETS2","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (mutagenesis, radiolabeling, phosphoamino acid analysis) in one rigorous study, replicated in subsequent papers","pmids":["8552081"],"is_preprint":false},{"year":1998,"finding":"MAP kinases p42 and p44 (ERK1/2) are the major ETS2 kinases downstream of CSF-1/c-fms signaling, phosphorylating ETS2 at Thr-72 in primary macrophages and fibroblasts; persistent ERK activation correlates with activation of the urokinase plasminogen activator (uPA) target gene.","method":"Phospho-specific antibody against pThr-72, immune depletion of MAP kinases, MEK inhibitor PD98059, in vitro kinase assays with recombinant ETS2, conditional raf kinase expression","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with recombinant substrate, immune depletion, pharmacological inhibition, and functional gene expression readout","pmids":["9710599"],"is_preprint":false},{"year":2004,"finding":"MAPK phosphorylation of ETS2 (and ETS1) at the conserved Thr-72 site results in enhanced transactivation through preferential, direct recruitment of the coactivators CBP and p300; both the phosphoacceptor site and the Pointed (PNT) domain are required for this interaction.","method":"Affinity chromatography screen of HeLa nuclear extracts using mock-treated vs ERK2-phosphorylated ETS proteins, binding assays with purified proteins, co-immunoprecipitation in vivo, reporter assays with MEK1 and CBP co-expression","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct binding with purified proteins, confirmed in vivo by co-IP, multiple orthogonal methods in one study","pmids":["15572696"],"is_preprint":false},{"year":2001,"finding":"CDK10 interacts with the N-terminus (Pointed domain) of ETS2 and inhibits ETS2 transactivation activity; ETS2 requires an intact Pointed domain to bind CDK10, and CDK10 does not recognize ETS1 in a two-hybrid assay.","method":"Yeast two-hybrid assay, in vitro binding, co-immunoprecipitation in mammalian cells, reporter transactivation assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and in vitro binding, single lab, two orthogonal methods","pmids":["11313931"],"is_preprint":false},{"year":2013,"finding":"CDK10 functions as a cyclin-dependent kinase activated by cyclin M (FAM58A product); CDK10/cyclin M phosphorylates ETS2 in vitro and positively controls ETS2 degradation by the proteasome, thereby negatively regulating ETS2 protein levels and downstream MAPK pathway activation.","method":"In vitro kinase assay, cyclin M co-expression/silencing, proteasome inhibitor experiments, analysis of STAR syndrome patient cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay, genetic validation in patient-derived cells, multiple orthogonal methods","pmids":["24218572"],"is_preprint":false},{"year":1998,"finding":"Targeted deletion of the ETS2 DNA-binding domain causes defective trophoblast function; ETS2 is required for MMP-9 expression in trophoblasts and mediates FGF-induced MMP-3 and MMP-13 expression in fibroblasts; ectopic ETS2 rescues MMP expression in Ets2-deficient fibroblasts.","method":"Gene targeting/knockout mouse, tetraploid aggregation rescue, Northern blot/gene expression, ectopic expression rescue","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — targeted gene deletion with rescue experiment, multiple cell types, multiple target genes validated","pmids":["9573048"],"is_preprint":false},{"year":2007,"finding":"Trophoblast stem cell self-renewal requires ETS2; conditional Ets2 inactivation decreases expression of Cdx2 (a direct Ets2 target) and other self-renewal genes while increasing differentiation-associated gene expression.","method":"Conditional gene targeting, gene expression analysis, chromatin immunoprecipitation identifying Cdx2 as a direct Ets2 target","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO, direct target validation by ChIP, multiple orthogonal methods","pmids":["17977525"],"is_preprint":false},{"year":2006,"finding":"ETS2 is required in trophoblast for anteroposterior axis patterning of the embryo; Ets2 mutants show reduced extraembryonic ectoderm (EXE) markers, and physical removal of EXE phenocopies Ets2 mutant patterning defects, placing ETS2 downstream of FGF signals in EXE cells that relay patterning signals to the epiblast.","method":"Genetic knockout/epistasis, tetraploid aggregation, embryo culture/physical excision of EXE, gene expression analysis","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with multiple rescue/phenocopy experiments, replicated observations","pmids":["16481355"],"is_preprint":false},{"year":2009,"finding":"ETS1 and ETS2 have essential and overlapping functions in endothelial cell survival during embryonic angiogenesis; double mutation of both factors causes embryonic lethality with vascular defects, loss of Mmp9, Bcl-XL, and cIAP2 expression, and increased endothelial apoptosis, with both factors loaded at target promoters.","method":"Conditional Cre/loxP knockout (endothelial-specific), chromatin immunoprecipitation, gene expression profiling of isolated embryonic endothelial cells, apoptosis assays in vivo and in vitro","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional cell-type-specific KO, ChIP confirming direct target occupancy, multiple orthogonal readouts","pmids":["19411629"],"is_preprint":false},{"year":2010,"finding":"ETS2 in tumor-associated macrophages (TAMs) drives a transcriptional program that represses anti-angiogenic gene inhibitors, promotes angiogenesis, and supports breast cancer lung metastasis; conditional Ets2 deletion in TAMs decreases metastasis frequency and tumor angiogenesis.","method":"Conditional knockout in macrophages (Cre/loxP), expression profiling, chromatin immunoprecipitation, multiple mouse mammary tumor models","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional cell-type-specific KO, ChIP, three independent tumor models, multiple orthogonal readouts","pmids":["20145133"],"is_preprint":false},{"year":2012,"finding":"Mutant p53 (gain-of-function) interacts with ETS2 to regulate gene expression through ETS-binding sites; this complex transactivates TDP2 (a DNA repair enzyme) to promote etoposide resistance in cancer cells.","method":"Genome-wide chromatin immunoprecipitation (ChIP), co-immunoprecipitation of mtp53 and ETS2, reporter assays, siRNA knockdown of TDP2","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, genome-wide ChIP with motif analysis, functional siRNA knockdown, multiple orthogonal methods","pmids":["22508727"],"is_preprint":false},{"year":2013,"finding":"ETS2 in tumor fibroblasts promotes angiogenesis in breast cancer; conditional Ets2 deletion in stromal fibroblasts reduces tumor growth and vascularization, and ETS2 in fibroblasts directly promotes blood vessel formation in an in vivo angiogenesis assay independent of tumor cells.","method":"Conditional knockout in fibroblasts, gene expression profiling, in vivo angiogenesis assay, multiple PyMT and ErbB2 tumor models","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional cell-type-specific KO in two tumor models, in vivo angiogenesis assay, multiple orthogonal readouts","pmids":["23977064"],"is_preprint":false},{"year":2013,"finding":"ETS2 suppresses MET proto-oncogene phosphorylation in non-small cell lung cancer cells; ETS2 knockdown activates the HGF/MET pathway and increases cell migration and invasion, while MET knockdown attenuates invasion induced by ETS2 siRNA, placing ETS2 upstream of MET as a tumor suppressor.","method":"siRNA knockdown, overexpression, pathway/microarray analysis, MET phosphorylation assays","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis by double knockdown, phosphorylation readout, single lab","pmids":["23659968"],"is_preprint":false},{"year":2024,"finding":"ETS2 is a central regulator of human inflammatory macrophages; overexpressing ETS2 in resting macrophages reproduces the inflammatory state (including upregulation of TNF and IL-23) linked to chr21q22-associated inflammatory diseases, and ETS2 expression is amplified by a disease-associated intergenic haplotype on chr21q22.","method":"Functional genomics in primary human macrophages, ETS2 overexpression, gene expression profiling, identification of causal regulatory element, drug validation in vitro and ex vivo","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — gain-of-function in primary human cells, multiple orthogonal functional assays, rigorous regulatory genomics linking SNP to ETS2 expression","pmids":["38839969"],"is_preprint":false},{"year":2013,"finding":"ETS2 is required for LPS-induced miR-155 expression in macrophages; ETS2 directly binds to the miR-155 promoter at an Ets-binding site proximal to the transcription start site, and ETS2-deficient mice display decreased LPS-induced miR-155; IL-10 inhibits ETS2 expression to suppress miR-155.","method":"Promoter deletion/mutation analysis, chromatin immunoprecipitation, Ets2-deficient mice, overexpression and knockdown","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo mouse genetics, ChIP, promoter mutagenesis, multiple orthogonal methods","pmids":["24362029"],"is_preprint":false},{"year":2013,"finding":"HGF-MET signaling leads to accumulation of ETS2, which interacts with MLL (mixed lineage leukemia) histone methyltransferase to form a complex on MMP1 and MMP3 promoters; MLL trimethylates H3K4 at these promoters, activating transcription and promoting hepatocellular carcinoma invasion.","method":"Co-immunoprecipitation (ETS2-MLL complex), ChIP assays showing MLL-ETS2 occupancy and H3K4me3 at MMP1/MMP3 promoters, Mll-/-, Hgf-/-, Met-/- mouse phenotype comparisons","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, ChIP with histone modification readout, genetic validation across three mouse KO models","pmids":["23934123"],"is_preprint":false},{"year":2003,"finding":"ETS2 phosphorylation at Thr-72 (by MAP kinase) is required for stromal support of mammary tumor progression; Ets2A72/A72 knock-in mice (Thr-72 → Ala) have reduced mammary tumor size and decreased MMP-9 and MMP-3 expression in macrophages, indicating that MAP kinase activation of ETS2 acts in the stroma to regulate protease expression.","method":"Knock-in mouse (Thr-72→Ala point mutation), tumor transplant, gene expression analysis in isolated macrophages, multiple transgenic tumor models","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — precise knock-in mutagenesis in vivo, multiple tumor models, cell-type-specific phenotype","pmids":["14612405"],"is_preprint":false},{"year":2004,"finding":"Ets2 phosphorylation at Thr-72 mediates persistent inflammatory macrophage gene expression (TNF-α, CCL3, MMP-9, integrin αM, Bcl-X) in the motheaten viable model; the Ets2A72 allele reduces inflammation and macrophage survival in vivo, establishing that Thr-72 phosphorylation is required for Ets2's role in macrophage survival and inflammatory gene programs.","method":"Genetic combination of Ets2A72 knock-in allele with Hcph(me-v) mutation in mice, gene expression analysis in alveolar macrophages, apoptosis assays, LPS stimulation of bone marrow-derived macrophages","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic epistasis with knock-in allele, multiple target genes, functional phenotype","pmids":["15240733"],"is_preprint":false},{"year":2000,"finding":"In macrophages from motheaten-viable mice, ETS2 is phosphorylated at Thr-72 in a CSF-1/MAPK-independent manner; Akt immunoprecipitates catalyze Thr-72 phosphorylation of ETS2 in vitro, and the p54 JNK isoform co-immunoprecipitates with Akt and can act as an ETS2 kinase; PI3K inhibition reduces Ets-2 phosphorylation and Bcl-x expression.","method":"Phospho-specific Thr-72 antibody, Akt immunoprecipitate kinase assay with recombinant ETS2, co-immunoprecipitation of Akt and JNK, PI3K inhibitor (LY294002)","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with purified Akt immunoprecipitate, direct Co-IP, pharmacological validation, single lab","pmids":["11027273"],"is_preprint":false},{"year":2002,"finding":"PTEN overexpression blocks insulin-stimulated ETS2 phosphorylation at Thr-72 by inhibiting ERK/MAP kinase activation (not via PI3K/Akt); this effect is phosphatase activity-dependent and abrogates ETS2-driven uPA Ras-responsive enhancer activity.","method":"Overexpression of wild-type and phosphatase-dead PTEN, MEK inhibitor (PD590089), PI3K inhibitor (LY492002), phospho-Thr-72 antibody, reporter assays","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection of pathway, functional reporter readout, multiple inhibitors, single lab","pmids":["12095911"],"is_preprint":false},{"year":2021,"finding":"ETS2 is phosphorylated and activated by ERK1/2 in cardiomyocytes upon hypertrophic stimulation; ETS2 forms a complex with NFAT to bind promoters of hypertrophic genes (Rcan1.4, miR-223), linking ERK1/2 and calcineurin signaling; cardiomyocyte-specific ETS2 knockout protects mice from pressure overload-induced cardiac hypertrophy.","method":"Cardiomyocyte-specific conditional knockout mice, pressure overload model, calcineurin transgenic mouse silencing, ChIP for ETS2 and NFAT at target promoters, Co-IP of ETS2-NFAT complex, primary cardiomyocyte assays","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO in vivo, NFAT co-IP, ChIP, multiple orthogonal approaches in human and mouse samples","pmids":["33821668"],"is_preprint":false},{"year":2003,"finding":"ETS2 overexpression induces apoptosis dependent on the p53 pathway; in ETS2 transgenic mice, increased apoptosis correlates with elevated p53 and downstream p53 pathway factors; crossing with p53-/- mice genetically rescues thymic apoptosis in ETS2 transgenic mice.","method":"ETS2 transgenic mice, p53 knockout cross, thymic apoptosis assay, transfection with functional p53 in HeLa cells","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis rescue experiment (ETS2 tg × p53-/-), multiple cell/tissue systems","pmids":["12554679"],"is_preprint":false},{"year":2001,"finding":"ETS2 and PU.1 synergistically transactivate the bcl-x(L) promoter in macrophages; this synergy requires the transactivation domains of both proteins and is specific to ETS2 and PU.1 (not ETS1); ectopic co-expression of ETS2 and PU.1 increases macrophage survival upon CSF-1 withdrawal.","method":"Reporter transactivation assays, domain mapping/mutagenesis, overexpression in primary macrophages, cell survival assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reporter with domain mapping, overexpression in primary cells, single lab","pmids":["11278399"],"is_preprint":false},{"year":2001,"finding":"ETS2 physically interacts with glucocorticoid receptor (GR) and synergistically transactivates the cytochrome P-450c27 promoter; GR binding to an adjacent cryptic GRE enables ETS2 to bind a weak Ets-like site; the GR DNA-binding domain alone (without transactivation domain) suffices for synergy, and the ETS2 transactivation domain is required.","method":"Co-immunoprecipitation, chemical cross-linking, transactivation assays with deletion mutants, reporter assays with GR-ETS2 fusion proteins","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and cross-linking confirming direct interaction, domain mapping, single lab","pmids":["11279115"],"is_preprint":false},{"year":2017,"finding":"ETS2 interacts with the co-repressor ZMYND11 (BS69) through its N-terminus, resulting in weaker transcriptional activation compared to ETS1; this interaction allows ETS2 to compete for ETS1 binding sites and attenuate transcription, forming the molecular basis for ETS2's context-dependent tumor suppressive vs. oncogenic function.","method":"ETS1/ETS2 cistrome comparison (ChIP-seq), ETS1 deletion experiments, co-immunoprecipitation of ETS2-ZMYND11, reporter assays with N-terminal domain mutants","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq cistrome analysis, Co-IP, domain mapping, mechanistic model validated by multiple orthogonal methods","pmids":["28119415"],"is_preprint":false},{"year":2004,"finding":"ETS2 transactivates the CD13/APN promoter via an Ets-core motif in endothelial cells; a phosphorylation-defective ETS2 T72A mutant fails to transactivate CD13/APN; siRNA knockdown of ETS2 inhibits CD13/APN transcription and prevents endothelial capillary network formation.","method":"Reporter assays with Ets-core motif mutations, Ets2 T72A phosphorylation-deficient mutant, siRNA knockdown, endothelial morphogenesis assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — phosphorylation-defective mutant, siRNA knockdown, functional endothelial assay, multiple orthogonal methods","pmids":["14507917"],"is_preprint":false},{"year":1993,"finding":"ETS2 transactivates the human stromelysin (MMP-3) promoter via a proximal PEA-3 site; mutation of the proximal PEA-3 site significantly inhibits the TPA response, and ETS2 fails to transactivate promoters with mutated PEA-3 sites.","method":"Promoter deletion and point mutation analysis, co-transfection reporter assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter mutagenesis plus transactivation assay, single lab, single main method","pmids":["8463255"],"is_preprint":false},{"year":1996,"finding":"ETS2 binds to ETS-binding site palindromes in the p53 promoter in gel-shift assays and activates p53 reporter expression 5–10-fold in COS cells; p53 mRNA levels are higher in NIH3T3 cells overexpressing ETS2, suggesting ETS2 is a transcriptional regulator of p53.","method":"Gel shift/EMSA assay with palindromic EBS oligonucleotides, CAT reporter co-transfection, Northern blot in ETS2-overexpressing cells","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct DNA binding assay plus reporter assay plus gene expression, single lab","pmids":["8649821"],"is_preprint":false},{"year":2004,"finding":"ETS2 directly binds to EBS -93 in the HO-1 promoter (shown by gel shift) and transactivates HO-1 expression in macrophages; mutation of the ETS2 DNA-binding domain prevents HO-1 transactivation; dominant negative ETS2 blunts LPS-induced HO-1 expression.","method":"Promoter deletion analysis, gel shift/EMSA, DNA-binding domain mutation, dominant negative ETS2, reporter assays, kinase inhibitors","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct DNA binding confirmed by EMSA, domain mutagenesis, functional readout, single lab","pmids":["15590657"],"is_preprint":false},{"year":2010,"finding":"ETS2 (and ETS1) directly bind to an Ets-binding site ~71–100 bp upstream of the miR-126 transcriptional start site and regulate miR-126 expression; knockdown of endogenous ETS1 and ETS2 decreases miR-126 expression in endothelial cells.","method":"Promoter mutation analysis, chromatin immunoprecipitation (ChIP), siRNA knockdown, reporter assays","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming occupancy, promoter mutagenesis, knockdown validation, single lab","pmids":["20671229"],"is_preprint":false},{"year":2010,"finding":"ETS2 activates MKP3/DUSP6 transcription downstream of ERK1/2 activation in MCF-7 breast cancer cells; ETS2-dependent MKP3/DUSP6 induction provides a negative feedback on ERK1/2 activity and shifts the proliferation/growth arrest decision.","method":"Reporter assays, knockdown, ETS2 overexpression, ERK1/2 activity measurements, MKP3 induction analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct transcriptional regulation confirmed by reporter and knockdown, single lab, functional cellular readout","pmids":["20554528"],"is_preprint":false},{"year":2012,"finding":"ETS2 and MESP1 co-expression converts human dermal fibroblasts into cardiac progenitors (KDR+ cells); ETS2 alone drives cardiac mesoderm commitment in embryonic stem cells, but neither ETS2 nor MESP1 alone generates cardiac progenitors from fibroblasts de novo.","method":"Lentivirus-mediated forced expression, embryonic stem cell differentiation assays, Ca2+ transient measurements, sarcomere detection, cardiac transcription factor marker analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional cellular reprogramming with multiple lineage markers, single lab","pmids":["22826236"],"is_preprint":false},{"year":2009,"finding":"ETS2 overexpression promotes megakaryocyte expansion from wild-type and Gata1-mutant fetal liver progenitors; overexpression of ETS2 facilitates expansion of CD41+ cells from Gata1s knockin progenitors and synergizes with Gata1 mutations to reduce more mature CD42+ fractions.","method":"Retroviral overexpression in murine fetal liver progenitors, flow cytometry, serial replating assays, JAK/STAT pathway analysis","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — overexpression in primary progenitors with genetic background variation, functional colony assay, single lab","pmids":["19168790"],"is_preprint":false},{"year":2016,"finding":"ETS2 in pancreatic stromal fibroblasts directly binds regulatory sequences of chemokine genes (Ccl3, Ccl4, Cxcl4, Cxcl5, Cxcl10) and regulates immune cell recruitment; conditional Ets2 deletion in fibroblasts increases CD8+ T cells and decreases Tregs and myeloid-derived suppressor cells during acinar-to-ductal metaplasia.","method":"Conditional Ets2 knockout in fibroblasts, ChIP on chemokine promoters, immune cell flow cytometry in pancreatic ADM model","journal":"Neoplasia","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional cell-type-specific KO, direct ChIP binding at multiple chemokine loci, functional immune phenotype","pmids":["27659014"],"is_preprint":false},{"year":2020,"finding":"ETS2 directly binds the IL-6 promoter and inhibits IL-6 transcription; ETS2 also suppresses ERK1/2, JNK, p38, and p65 activation downstream of LPS and VSV, functioning as a negative regulator of macrophage inflammatory responses.","method":"ChIP assay on IL-6 promoter, ETS2 knockout mice, siRNA knockdown, CLP-induced sepsis model, kinase activation assays (Western blot)","journal":"Aging","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming direct promoter binding, in vivo KO model, single lab","pmids":["31785145"],"is_preprint":false},{"year":2003,"finding":"ETS2 transactivates the beta-APP (amyloid precursor protein) gene via specific ETS-binding sites in the beta-APP promoter and cooperates with AP1; ETS2 transgenic mouse brains and neuronal cultures display elevated beta-APP protein, increased presenilin-1, and increased beta-amyloid production.","method":"Reporter assays with EBS mutations, ETS2 transgenic mice, Western blot for APP/presenilin-1/beta-amyloid","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter plus in vivo transgenic validation, single lab","pmids":["12890557"],"is_preprint":false},{"year":2009,"finding":"ETS2 and p53 mediate cAMP/PKA-induced MMP-2 expression and trophoblast invasion; antisense inhibition of ETS2 or p53 reduces MMP-2 mRNA, secretion, and invasiveness in forskolin-treated trophoblast cells; ETS2 binds to its consensus site in the MMP-2 promoter in response to forskolin.","method":"EMSA binding assay, Northern blot/RT-PCR, antisense transfection, zymography, transwell invasion assay","journal":"Reproductive biology and endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct DNA binding by EMSA, functional antisense knockdown, multiple readouts, single lab","pmids":["19939245"],"is_preprint":false},{"year":1995,"finding":"ETS2 transactivates the cdc2 gene promoter via specific ETS-binding sites; cells constitutively expressing ETS2 have increased cdc2 expression, elevated histone H1 kinase activity, and higher cyclin A (but not cyclin B1) levels, and can grow under low serum conditions.","method":"Reporter transactivation assays with EBS mutations, constitutive ETS2 expression in BALB/c3T3, kinase assays, Western blot for cyclins","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter with site mutation, gain-of-function with kinase assay readout, single lab","pmids":["7867724"],"is_preprint":false},{"year":1996,"finding":"Constitutive ETS2 expression in M1D+ myeloblast cells is sufficient to drive macrophage differentiation; ETS2 directly activates junB transcription via Ets-binding sites in the junB promoter, as shown by reporter assays and dominant negative ETS2 inhibition.","method":"Stable ETS2 transfection, differentiation marker analysis, transient reporter assays with junB promoter EBS, dominant negative ETS2","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — stable transfection with direct junB promoter target validation by reporter + dominant negative, single lab","pmids":["8943340"],"is_preprint":false},{"year":2019,"finding":"EGF activates ETS2 via MEK and PI3K pathways, and phosphorylated ETS2 (Thr-72) suppresses miR-124a promoter activity in pancreatic beta cells; ETS2 binds conserved AGGAANA/TN motifs in three miR-124a promoters; ETS2 knockdown reduces and overexpression promotes insulin biosynthesis.","method":"Kinase inhibitors (MEK and PI3K), ETS2 phosphorylation analysis, reporter assays with promoter EBS mutations, ETS2 knockdown/overexpression, insulin secretion/biosynthesis assays","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter with mutagenesis, phosphorylation-specific readout, functional insulin biosynthesis assay, single lab","pmids":["31754329"],"is_preprint":false}],"current_model":"ETS2 is a transcription factor that is activated downstream of Ras/MAPK signaling via phosphorylation of a conserved Thr-72 residue by ERK1/2 (and in some contexts by Akt/JNK), which recruits CBP/p300 coactivators and enhances transactivation of target genes including MMPs, Bcl-XL, CD13/APN, HO-1, miR-155, miR-126, cdc2, beta-APP, and IL-6; CDK10/cyclin M phosphorylates ETS2 to promote its proteasomal degradation; ETS2 forms functional complexes with NFAT (in cardiomyocytes), MLL (in HGF-MET signaling), glucocorticoid receptor, PU.1, and gain-of-function mutant p53; its context-dependent oncogenic vs. tumor-suppressive activity is governed in part by interaction with the co-repressor ZMYND11; ETS2 is essential for trophoblast stem cell self-renewal (via Cdx2), embryonic anteroposterior axis patterning, endothelial cell survival during angiogenesis, and macrophage inflammatory gene programs, with Thr-72 phosphorylation status being a critical regulatory node for all these functions."},"narrative":{"mechanistic_narrative":"ETS2 is a sequence-specific transcription factor that converts Ras/MAPK signaling into target-gene programs governing tissue remodeling, angiogenesis, cell survival, and inflammation [PMID:8552081, PMID:9573048]. Its central regulatory event is phosphorylation of the conserved Thr-72 residue: ERK1/2 (p42/p44) are the principal ETS2 kinases downstream of growth-factor and CSF-1 signaling [PMID:9710599], and in selected contexts Akt and the p54 JNK isoform also catalyze Thr-72 phosphorylation [PMID:11027273]. Phosphorylated Thr-72, together with the Pointed (PNT) domain, recruits the coactivators CBP and p300 to drive transactivation [PMID:15572696], whereas Thr-72-to-Ala knock-in mice lose stromal protease expression, macrophage survival, and inflammatory gene programs in vivo, establishing this residue as the obligate node for ETS2 output [PMID:14612405, PMID:15240733]. ETS2 binds Ets-core motifs at numerous promoters to control proteases (MMP-3, MMP-9, MMP-13), survival genes (Bcl-XL), CD13/APN, HO-1, miR-155, and miR-126, and is required for trophoblast stem-cell self-renewal through direct activation of Cdx2 and for embryonic anteroposterior axis patterning in extraembryonic ectoderm [PMID:9573048, PMID:17977525, PMID:16481355, PMID:19411629, PMID:24362029, PMID:14507917, PMID:15590657]. ETS1 and ETS2 act redundantly to maintain endothelial survival during angiogenesis [PMID:19411629], and stromal ETS2 in tumor-associated macrophages and fibroblasts promotes angiogenesis, immune-cell recruitment, and metastasis [PMID:20145133, PMID:23977064, PMID:27659014]. ETS2 protein levels are limited by CDK10/cyclin M, which phosphorylates ETS2 and targets it for proteasomal degradation [PMID:11313931, PMID:24218572]. Context-dependent oncogenic versus tumor-suppressive behavior arises from partner choice: ETS2 cooperates with PU.1, the glucocorticoid receptor, NFAT, MLL, and gain-of-function mutant p53 in activating contexts [PMID:22508727, PMID:23934123, PMID:33821668, PMID:11278399, PMID:11279115], but its N-terminal interaction with the co-repressor ZMYND11 weakens activation relative to ETS1 and lets ETS2 attenuate transcription by competing for shared Ets sites [PMID:28119415]. In human macrophages ETS2 is a master driver of the inflammatory state, with a chr21q22 disease-associated haplotype amplifying ETS2 expression [PMID:38839969].","teleology":[{"year":1996,"claim":"Established that Ras signaling acts on ETS2 through a single phosphorylation event, defining Thr-72 as the molecular switch for Ras-mediated activation.","evidence":"Reporter assays, site-directed mutagenesis (T72A), and phosphoamino acid analysis of radiolabeled ETS2","pmids":["8552081"],"confidence":"High","gaps":["Did not identify the physiological kinase","Did not define how phosphorylation alters transactivation mechanistically"]},{"year":1998,"claim":"Identified ERK1/2 as the major physiological ETS2 kinases downstream of CSF-1, connecting receptor signaling to Thr-72 phosphorylation and target-gene induction.","evidence":"Phospho-Thr-72 antibody, MAP kinase immune depletion, MEK inhibitor, in vitro kinase assays with recombinant ETS2 in macrophages and fibroblasts","pmids":["9710599"],"confidence":"High","gaps":["Did not resolve coactivator recruitment","Other kinase inputs not excluded"]},{"year":2000,"claim":"Showed Thr-72 can be phosphorylated independently of CSF-1/MAPK via Akt and p54 JNK, broadening the signaling inputs converging on ETS2.","evidence":"Akt and JNK immunoprecipitate kinase assays, Co-IP, PI3K inhibitor, in motheaten-viable macrophages","pmids":["11027273"],"confidence":"High","gaps":["Direct kinase identity within the immunoprecipitate not fully purified","Relative contribution of Akt vs JNK unresolved"]},{"year":2001,"claim":"Defined the Pointed domain as a docking site for CDK10, providing the first negative regulator of ETS2 transactivation.","evidence":"Yeast two-hybrid, in vitro binding, reciprocal Co-IP, reporter assays","pmids":["11313931"],"confidence":"Medium","gaps":["Kinase activity of CDK10 toward ETS2 not yet shown","Single lab"]},{"year":2001,"claim":"Demonstrated combinatorial control of survival genes by showing ETS2 synergizes with PU.1 and with the glucocorticoid receptor to activate distinct promoters.","evidence":"Reporter transactivation, domain mapping, Co-IP/cross-linking, macrophage survival assays","pmids":["11278399","11279115"],"confidence":"Medium","gaps":["Endogenous complex stoichiometry not defined","Single lab for each interaction"]},{"year":2003,"claim":"Proved in vivo that Thr-72 phosphorylation is required for ETS2's stromal and survival functions using a precise knock-in mutant.","evidence":"Ets2 T72A knock-in mice, tumor transplant, macrophage gene expression, motheaten-viable epistasis","pmids":["14612405","15240733"],"confidence":"High","gaps":["Did not separate which downstream kinase phosphorylates Thr-72 in each tissue"]},{"year":2003,"claim":"Placed ETS2 within the apoptotic/tumor-suppressive axis by showing its overexpression triggers p53-dependent apoptosis.","evidence":"ETS2 transgenic mice crossed to p53-/-, thymic apoptosis assays","pmids":["12554679"],"confidence":"High","gaps":["Mechanism by which ETS2 elevates p53 not fully resolved"]},{"year":2004,"claim":"Resolved the mechanistic basis of Thr-72 phosphorylation by showing it drives preferential recruitment of CBP/p300 coactivators, requiring both the phosphosite and the PNT domain.","evidence":"Affinity chromatography of nuclear extracts, purified-protein binding, in vivo Co-IP, reporter assays","pmids":["15572696"],"confidence":"High","gaps":["Structural basis of phospho-dependent coactivator binding not solved"]},{"year":2008,"claim":"Mapped direct ETS2 target promoters across diverse genes, defining its Ets-core DNA-binding repertoire (CD13/APN, HO-1, MMP-3, p53, junB, cdc2, beta-APP).","evidence":"EMSA, promoter mutagenesis, reporter assays, dominant-negative and siRNA across multiple studies","pmids":["14507917","15590657","8463255","8649821","8943340","7867724","12890557"],"confidence":"Medium","gaps":["Several targets validated in single labs","In vivo occupancy not confirmed for all"]},{"year":2009,"claim":"Established essential developmental and vascular roles, including redundancy with ETS1 in endothelial survival and direct activation of self-renewal/angiogenic targets.","evidence":"Endothelial- and trophoblast-specific conditional knockouts, ChIP, gene expression profiling, apoptosis assays","pmids":["19411629","17977525","16481355","9573048"],"confidence":"High","gaps":["Degree of ETS1/ETS2 functional overlap across tissues not fully mapped"]},{"year":2013,"claim":"Defined the CDK10/cyclin M kinase complex as the degradation-promoting regulator that sets ETS2 protein levels and dampens MAPK output.","evidence":"In vitro kinase assays, cyclin M silencing, proteasome inhibition, STAR syndrome patient cells","pmids":["24218572"],"confidence":"High","gaps":["E3 ligase recognizing phosphorylated ETS2 not identified"]},{"year":2013,"claim":"Revealed stromal and tumor-cell-context functions, including MLL-dependent H3K4me3 deposition at MMP promoters and dual oncogenic vs tumor-suppressive roles via MET.","evidence":"Co-IP, ChIP with histone-mark readout, conditional fibroblast KO, siRNA epistasis in lung and hepatocellular cancer models","pmids":["23934123","23977064","23659968","20145133","22508727"],"confidence":"High","gaps":["Contextual determinants of oncogenic vs suppressive output not unified","MET-suppression mechanism characterized in single lab"]},{"year":2017,"claim":"Provided a molecular explanation for ETS2's context-dependent dual function through its N-terminal ZMYND11 co-repressor interaction and competition with ETS1.","evidence":"ETS1/ETS2 ChIP-seq cistrome comparison, Co-IP, N-terminal domain mutants, reporter assays","pmids":["28119415"],"confidence":"High","gaps":["How signaling modulates the ETS2-ZMYND11 balance in vivo not defined"]},{"year":2021,"claim":"Connected ERK1/2 and calcineurin signaling in the heart by showing ETS2-NFAT complexes drive hypertrophic gene expression.","evidence":"Cardiomyocyte-specific KO, pressure overload model, ChIP, ETS2-NFAT Co-IP","pmids":["33821668"],"confidence":"High","gaps":["Whether NFAT partnership extends to non-cardiac contexts unknown"]},{"year":2024,"claim":"Established ETS2 as a master driver of human inflammatory macrophages and linked its dysregulation to a chr21q22 disease haplotype.","evidence":"Functional genomics in primary human macrophages, ETS2 overexpression, causal regulatory element mapping, drug validation","pmids":["38839969"],"confidence":"High","gaps":["Full set of downstream effector genes in human disease not enumerated","Therapeutic targeting validated only in vitro/ex vivo"]},{"year":null,"claim":"It remains unresolved how a single transcription factor integrates competing activating partners (CBP/p300, PU.1, NFAT, MLL, mutant p53) versus repressive interactions (ZMYND11) to produce cell-type-specific oncogenic, tumor-suppressive, developmental, or inflammatory outcomes.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural model of phospho-dependent partner selection","E3 ligase for CDK10-primed degradation unidentified","Determinants of ETS1 vs ETS2 site choice in shared cistromes unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,5,24,26]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[27,28,29,36,37]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[4]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,24]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[5,8,14,24]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[13,14,17,33]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,7]}],"complexes":[],"partners":["CBP","EP300","CDK10","ZMYND11","NFAT","MLL","PU.1","TP53"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P15036","full_name":"Protein C-ets-2","aliases":[],"length_aa":469,"mass_kda":53.0,"function":"Transcription factor activating transcription. Binds specifically the DNA GGAA/T core motif (Ets-binding site or EBS) in gene promoters and stimulates transcription","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P15036/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ETS2","classification":"Not Classified","n_dependent_lines":9,"n_total_lines":1208,"dependency_fraction":0.0074503311258278145},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ETS2","total_profiled":1310},"omim":[{"mim_id":"617180","title":"CHITAYAT SYNDROME; CHYTS","url":"https://www.omim.org/entry/617180"},{"mim_id":"611888","title":"ETS2 REPRESSOR FACTOR; ERF","url":"https://www.omim.org/entry/611888"},{"mim_id":"611723","title":"CHROMOSOME 21 OPEN READING FRAME 24; C21ORF24","url":"https://www.omim.org/entry/611723"},{"mim_id":"611585","title":"TESCALCIN; TESC","url":"https://www.omim.org/entry/611585"},{"mim_id":"605474","title":"TOLL-LIKE RECEPTOR 9; TLR9","url":"https://www.omim.org/entry/605474"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"},{"location":"Plasma membrane","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ETS2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P15036","domains":[{"cath_id":"1.10.150.50","chopping":"81-173","consensus_level":"high","plddt":83.5733,"start":81,"end":173},{"cath_id":"1.10.10.10","chopping":"350-460","consensus_level":"high","plddt":94.0875,"start":350,"end":460}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P15036","model_url":"https://alphafold.ebi.ac.uk/files/AF-P15036-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P15036-F1-predicted_aligned_error_v6.png","plddt_mean":62.84},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ETS2","jax_strain_url":"https://www.jax.org/strain/search?query=ETS2"},"sequence":{"accession":"P15036","fasta_url":"https://rest.uniprot.org/uniprotkb/P15036.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P15036/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P15036"}},"corpus_meta":[{"pmid":"8552081","id":"PMC_8552081","title":"Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8552081","citation_count":330,"is_preprint":false},{"pmid":"9573048","id":"PMC_9573048","title":"Defective trophoblast function in mice with a targeted mutation of Ets2.","date":"1998","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9573048","citation_count":255,"is_preprint":false},{"pmid":"20978205","id":"PMC_20978205","title":"EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20978205","citation_count":239,"is_preprint":false},{"pmid":"2209540","id":"PMC_2209540","title":"The product of the c-ets-1 proto-oncogene and the related Ets2 protein act as transcriptional activators of the long terminal repeat of human T cell leukemia virus HTLV-1.","date":"1990","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/2209540","citation_count":236,"is_preprint":false},{"pmid":"17332326","id":"PMC_17332326","title":"Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17332326","citation_count":232,"is_preprint":false},{"pmid":"8183549","id":"PMC_8183549","title":"Differential expression of ets-1 and ets-2 proto-oncogenes during murine embryogenesis.","date":"1994","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8183549","citation_count":191,"is_preprint":false},{"pmid":"22508727","id":"PMC_22508727","title":"Mutant p53 cooperates with ETS2 to promote etoposide resistance.","date":"2012","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/22508727","citation_count":173,"is_preprint":false},{"pmid":"15572696","id":"PMC_15572696","title":"Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15572696","citation_count":172,"is_preprint":false},{"pmid":"2187191","id":"PMC_2187191","title":"Reciprocal expression of human ETS1 and ETS2 genes during T-cell activation: regulatory role for the protooncogene ETS1.","date":"1990","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2187191","citation_count":166,"is_preprint":false},{"pmid":"8596630","id":"PMC_8596630","title":"Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice.","date":"1996","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8596630","citation_count":164,"is_preprint":false},{"pmid":"22826236","id":"PMC_22826236","title":"Transcription factors ETS2 and MESP1 transdifferentiate human dermal fibroblasts into cardiac progenitors.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22826236","citation_count":161,"is_preprint":false},{"pmid":"19411629","id":"PMC_19411629","title":"Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19411629","citation_count":153,"is_preprint":false},{"pmid":"15007164","id":"PMC_15007164","title":"Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15007164","citation_count":145,"is_preprint":false},{"pmid":"20671229","id":"PMC_20671229","title":"Ets-1 and Ets-2 regulate the expression of microRNA-126 in endothelial cells.","date":"2010","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20671229","citation_count":131,"is_preprint":false},{"pmid":"23659968","id":"PMC_23659968","title":"ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer.","date":"2013","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/23659968","citation_count":129,"is_preprint":false},{"pmid":"38839969","id":"PMC_38839969","title":"A disease-associated gene desert directs macrophage inflammation through ETS2.","date":"2024","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/38839969","citation_count":114,"is_preprint":false},{"pmid":"8463255","id":"PMC_8463255","title":"A polyomavirus enhancer A-binding protein-3 site and Ets-2 protein have a major role in the 12-O-tetradecanoylphorbol-13-acetate response of the human stromelysin gene.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8463255","citation_count":111,"is_preprint":false},{"pmid":"15788656","id":"PMC_15788656","title":"Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer.","date":"2005","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15788656","citation_count":105,"is_preprint":false},{"pmid":"19168790","id":"PMC_19168790","title":"ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19168790","citation_count":97,"is_preprint":false},{"pmid":"20145133","id":"PMC_20145133","title":"An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20145133","citation_count":97,"is_preprint":false},{"pmid":"11313931","id":"PMC_11313931","title":"Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11313931","citation_count":93,"is_preprint":false},{"pmid":"24362029","id":"PMC_24362029","title":"The role of Ets2 transcription factor in the induction of microRNA-155 (miR-155) by lipopolysaccharide and its targeting by interleukin-10.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24362029","citation_count":91,"is_preprint":false},{"pmid":"10212281","id":"PMC_10212281","title":"Regulation of the human interleukin-5 promoter by Ets transcription factors. Ets1 and Ets2, but not Elf-1, cooperate with GATA3 and HTLV-I Tax1.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10212281","citation_count":90,"is_preprint":false},{"pmid":"9710599","id":"PMC_9710599","title":"Persistent activation of mitogen-activated protein kinases p42 and p44 and ets-2 phosphorylation in response to colony-stimulating factor 1/c-fms signaling.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9710599","citation_count":88,"is_preprint":false},{"pmid":"21989915","id":"PMC_21989915","title":"Analysis of gene networks in white adipose tissue development reveals a role for ETS2 in adipogenesis.","date":"2011","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21989915","citation_count":85,"is_preprint":false},{"pmid":"15314206","id":"PMC_15314206","title":"Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells.","date":"2004","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/15314206","citation_count":81,"is_preprint":false},{"pmid":"12554679","id":"PMC_12554679","title":"ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway.","date":"2003","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12554679","citation_count":80,"is_preprint":false},{"pmid":"16737810","id":"PMC_16737810","title":"Ets2 binding site single nucleotide polymorphism at the hTERT gene promoter--effect on telomerase expression and telomere length maintenance in non-small cell lung cancer.","date":"2006","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/16737810","citation_count":79,"is_preprint":false},{"pmid":"2405393","id":"PMC_2405393","title":"Molecular and functional characterization of the promoter of ETS2, the human c-ets-2 gene.","date":"1990","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2405393","citation_count":74,"is_preprint":false},{"pmid":"33821668","id":"PMC_33821668","title":"Cooperative Binding of ETS2 and NFAT Links Erk1/2 and Calcineurin Signaling in the Pathogenesis of Cardiac Hypertrophy.","date":"2021","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/33821668","citation_count":70,"is_preprint":false},{"pmid":"24218572","id":"PMC_24218572","title":"CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24218572","citation_count":69,"is_preprint":false},{"pmid":"16481355","id":"PMC_16481355","title":"Ets2 is necessary in trophoblast for normal embryonic anteroposterior axis development.","date":"2006","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16481355","citation_count":66,"is_preprint":false},{"pmid":"9879994","id":"PMC_9879994","title":"ETS2 function is required to maintain the transformed state of human prostate cancer cells.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9879994","citation_count":66,"is_preprint":false},{"pmid":"17977525","id":"PMC_17977525","title":"Ets2 is required for trophoblast stem cell self-renewal.","date":"2007","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/17977525","citation_count":65,"is_preprint":false},{"pmid":"12095911","id":"PMC_12095911","title":"PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway.","date":"2002","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12095911","citation_count":63,"is_preprint":false},{"pmid":"11027273","id":"PMC_11027273","title":"ets-2 is a target for an akt (Protein kinase B)/jun N-terminal kinase signaling pathway in macrophages of motheaten-viable mutant mice.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11027273","citation_count":63,"is_preprint":false},{"pmid":"25241894","id":"PMC_25241894","title":"CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25241894","citation_count":61,"is_preprint":false},{"pmid":"8649821","id":"PMC_8649821","title":"ETS1 and ETS2 in p53 regulation: spatial separation of ETS binding sites (EBS) modulate protein: DNA interaction.","date":"1996","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8649821","citation_count":59,"is_preprint":false},{"pmid":"2186967","id":"PMC_2186967","title":"Rapid and transient expression of Ets2 in mature macrophages following stimulation with cMGF, LPS, and PKC activators.","date":"1990","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/2186967","citation_count":57,"is_preprint":false},{"pmid":"9303349","id":"PMC_9303349","title":"Ets-1 and Ets-2 proto-oncogenes exhibit differential and restricted expression patterns during Xenopus laevis oogenesis and embryogenesis.","date":"1997","source":"The International journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/9303349","citation_count":57,"is_preprint":false},{"pmid":"12560478","id":"PMC_12560478","title":"Selective inhibition of transcription of the Ets2 gene in prostate cancer cells by a triplex-forming oligonucleotide.","date":"2003","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/12560478","citation_count":54,"is_preprint":false},{"pmid":"21700929","id":"PMC_21700929","title":"Ets2 determines the inflammatory state of endothelial cells in advanced atherosclerotic lesions.","date":"2011","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/21700929","citation_count":54,"is_preprint":false},{"pmid":"14507917","id":"PMC_14507917","title":"CD13/APN transcription is induced by RAS/MAPK-mediated phosphorylation of Ets-2 in activated endothelial cells.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14507917","citation_count":54,"is_preprint":false},{"pmid":"23934123","id":"PMC_23934123","title":"HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23934123","citation_count":53,"is_preprint":false},{"pmid":"9605774","id":"PMC_9605774","title":"Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines.","date":"1998","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9605774","citation_count":53,"is_preprint":false},{"pmid":"14612405","id":"PMC_14612405","title":"Ets2-dependent stromal regulation of mouse mammary tumors.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14612405","citation_count":52,"is_preprint":false},{"pmid":"22298639","id":"PMC_22298639","title":"Transcriptional regulation of miR-196b by ETS2 in gastric cancer cells.","date":"2012","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22298639","citation_count":51,"is_preprint":false},{"pmid":"10454570","id":"PMC_10454570","title":"Role of distinct mitogen-activated protein kinase pathways and cooperation between Ets-2, ATF-2, and Jun family members in human urokinase-type plasminogen activator gene induction by interleukin-1 and tetradecanoyl phorbol acetate.","date":"1999","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10454570","citation_count":51,"is_preprint":false},{"pmid":"15590657","id":"PMC_15590657","title":"Role of Ets-2 in the regulation of heme oxygenase-1 by endotoxin.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15590657","citation_count":49,"is_preprint":false},{"pmid":"9668063","id":"PMC_9668063","title":"Elevated expression of Ets2 or distinct portions of Ets2 can reverse Ras-mediated cellular transformation.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9668063","citation_count":48,"is_preprint":false},{"pmid":"11278399","id":"PMC_11278399","title":"Bcl-XL expression correlates with primary macrophage differentiation, activation of functional competence, and survival and results from synergistic transcriptional activation by Ets2 and PU.1.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278399","citation_count":48,"is_preprint":false},{"pmid":"8660103","id":"PMC_8660103","title":"Constitutive expression of c-fos and c-jun, overexpression of ets-2, and reduced expression of metastasis suppressor gene nm23-H1 in rheumatoid arthritis.","date":"1996","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/8660103","citation_count":48,"is_preprint":false},{"pmid":"10485465","id":"PMC_10485465","title":"A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10485465","citation_count":48,"is_preprint":false},{"pmid":"20554528","id":"PMC_20554528","title":"Differential up-regulation of MAP kinase phosphatases MKP3/DUSP6 and DUSP5 by Ets2 and c-Jun converge in the control of the growth arrest versus proliferation response of MCF-7 breast cancer cells to phorbol ester.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20554528","citation_count":47,"is_preprint":false},{"pmid":"14678752","id":"PMC_14678752","title":"Overexpression of the chromosome 21 transcription factor Ets2 induces neuronal apoptosis.","date":"2003","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/14678752","citation_count":47,"is_preprint":false},{"pmid":"15240733","id":"PMC_15240733","title":"Activated Ets2 is required for persistent inflammatory responses in the motheaten viable model.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15240733","citation_count":46,"is_preprint":false},{"pmid":"29974077","id":"PMC_29974077","title":"Aberrant expression of ETS1 and ETS2 proteins in cancer.","date":"2018","source":"Cancer reports and reviews","url":"https://pubmed.ncbi.nlm.nih.gov/29974077","citation_count":45,"is_preprint":false},{"pmid":"7523384","id":"PMC_7523384","title":"Ets-2 and c-Myb act independently in regulating expression of the hematopoietic stem cell antigen CD34.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7523384","citation_count":40,"is_preprint":false},{"pmid":"14976186","id":"PMC_14976186","title":"Unique and selective effects of five Ets family members, Elf3, Ets1, Ets2, PEA3, and PU.1, on the promoter of the type II transforming growth factor-beta receptor gene.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14976186","citation_count":38,"is_preprint":false},{"pmid":"18094719","id":"PMC_18094719","title":"The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy.","date":"2007","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/18094719","citation_count":38,"is_preprint":false},{"pmid":"8943340","id":"PMC_8943340","title":"Constitutive c-ets2 expression in M1D+ myeloblast leukemic cells induces their differentiation to macrophages.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8943340","citation_count":37,"is_preprint":false},{"pmid":"12391198","id":"PMC_12391198","title":"The role of the Ets2 transcription factor in the proliferation, maturation, and survival of mouse thymocytes.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12391198","citation_count":36,"is_preprint":false},{"pmid":"11279115","id":"PMC_11279115","title":"Physical interaction and functional synergy between glucocorticoid receptor and Ets2 proteins for transcription activation of the rat cytochrome P-450c27 promoter.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11279115","citation_count":36,"is_preprint":false},{"pmid":"31785145","id":"PMC_31785145","title":"Ets2 suppresses inflammatory cytokines through MAPK/NF-κB signaling and directly binds to the IL-6 promoter in macrophages.","date":"2019","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31785145","citation_count":35,"is_preprint":false},{"pmid":"32677671","id":"PMC_32677671","title":"RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer.","date":"2020","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/32677671","citation_count":34,"is_preprint":false},{"pmid":"27659014","id":"PMC_27659014","title":"Stromal ETS2 Regulates Chemokine Production and Immune Cell Recruitment during Acinar-to-Ductal Metaplasia.","date":"2016","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/27659014","citation_count":34,"is_preprint":false},{"pmid":"14693372","id":"PMC_14693372","title":"Detailed mapping of the ERG-ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16.","date":"2004","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/14693372","citation_count":33,"is_preprint":false},{"pmid":"19407855","id":"PMC_19407855","title":"Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas.","date":"2009","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/19407855","citation_count":32,"is_preprint":false},{"pmid":"31872468","id":"PMC_31872468","title":"Exosomal miR-663b targets Ets2-repressor factor to promote proliferation and the epithelial-mesenchymal transition of bladder cancer cells.","date":"2020","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/31872468","citation_count":32,"is_preprint":false},{"pmid":"7867724","id":"PMC_7867724","title":"ets-2 regulates cdc2 kinase activity in mammalian cells: coordinated expression of cdc2 and cyclin A.","date":"1995","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/7867724","citation_count":31,"is_preprint":false},{"pmid":"12890557","id":"PMC_12890557","title":"The chromosome 21 transcription factor ETS2 transactivates the beta-APP promoter: implications for Down syndrome.","date":"2003","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12890557","citation_count":30,"is_preprint":false},{"pmid":"23977064","id":"PMC_23977064","title":"Ets2 in tumor fibroblasts promotes angiogenesis in breast cancer.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23977064","citation_count":29,"is_preprint":false},{"pmid":"26274316","id":"PMC_26274316","title":"VEGFA Expression Is Inhibited by Arsenic Trioxide in HUVECs through the Upregulation of Ets-2 and miRNA-126.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26274316","citation_count":29,"is_preprint":false},{"pmid":"21425406","id":"PMC_21425406","title":"Ets2 regulates colonic stem cells and sensitivity to tumorigenesis.","date":"2011","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/21425406","citation_count":28,"is_preprint":false},{"pmid":"24277931","id":"PMC_24277931","title":"Transcription factor Ets1, but not the closely related factor Ets2, inhibits antibody-secreting cell differentiation.","date":"2013","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24277931","citation_count":28,"is_preprint":false},{"pmid":"16799155","id":"PMC_16799155","title":"The transcriptional ETS2 repressor factor associates with active and inactive Erks through distinct FXF motifs.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16799155","citation_count":28,"is_preprint":false},{"pmid":"31763674","id":"PMC_31763674","title":"ΔNp73/ETS2 complex drives glioblastoma pathogenesis- targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma.","date":"2020","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31763674","citation_count":27,"is_preprint":false},{"pmid":"31841990","id":"PMC_31841990","title":"Kcnq1ot1/miR-381-3p/ETS2 Axis Regulates Inflammation in Mouse Models of Acute Respiratory Distress Syndrome.","date":"2019","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/31841990","citation_count":27,"is_preprint":false},{"pmid":"31071529","id":"PMC_31071529","title":"MicroRNA-146b Overexpression Promotes Human Bladder Cancer Invasion via Enhancing ETS2-Mediated mmp2 mRNA Transcription.","date":"2019","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/31071529","citation_count":27,"is_preprint":false},{"pmid":"19566835","id":"PMC_19566835","title":"Ets2 transcription factor, telomerase activity and breast cancer.","date":"2009","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19566835","citation_count":26,"is_preprint":false},{"pmid":"27048589","id":"PMC_27048589","title":"ETS2 and Twist1 promote invasiveness of Helicobacter pylori-infected gastric cancer cells by inducing Siah2.","date":"2016","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/27048589","citation_count":26,"is_preprint":false},{"pmid":"1888697","id":"PMC_1888697","title":"Positive and negative factors regulate the transcription of the ETS2 gene via an oncogene-responsive-like unit within the ETS2 promoter region.","date":"1991","source":"Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/1888697","citation_count":26,"is_preprint":false},{"pmid":"9174050","id":"PMC_9174050","title":"Altered expression of Erg and Ets-2 transcription factors is associated with genetic changes at 21q22.2-22.3 in immortal and cervical carcinoma cell lines.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9174050","citation_count":26,"is_preprint":false},{"pmid":"28119415","id":"PMC_28119415","title":"Interaction with ZMYND11 mediates opposing roles of Ras-responsive transcription factors ETS1 and ETS2.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/28119415","citation_count":25,"is_preprint":false},{"pmid":"16380248","id":"PMC_16380248","title":"Ets2 transcription factor in normal and neoplastic human breast tissue.","date":"2005","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/16380248","citation_count":25,"is_preprint":false},{"pmid":"26925389","id":"PMC_26925389","title":"Mutant p53 and ETS2, a Tale of Reciprocity.","date":"2016","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26925389","citation_count":24,"is_preprint":false},{"pmid":"19764029","id":"PMC_19764029","title":"Complex contributions of Ets2 to craniofacial and thymus phenotypes of trisomic \"Down syndrome\" mice.","date":"2009","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/19764029","citation_count":24,"is_preprint":false},{"pmid":"19939245","id":"PMC_19939245","title":"Ets-2 and p53 mediate cAMP-induced MMP-2 expression, activity and trophoblast invasion.","date":"2009","source":"Reproductive biology and endocrinology : RB&E","url":"https://pubmed.ncbi.nlm.nih.gov/19939245","citation_count":23,"is_preprint":false},{"pmid":"9822660","id":"PMC_9822660","title":"Selective inhibition of prolactin gene transcription by the ETS-2 repressor factor.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9822660","citation_count":23,"is_preprint":false},{"pmid":"21584592","id":"PMC_21584592","title":"Influence of nucleotides flanking the ggaa core sequence on ets1 and ets2 DNA-binding activity and the mechanism of ets1 autoregulation.","date":"1992","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21584592","citation_count":23,"is_preprint":false},{"pmid":"17507653","id":"PMC_17507653","title":"Ets-2 repressor factor silences extrasynaptic utrophin by N-box mediated repression in skeletal muscle.","date":"2007","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/17507653","citation_count":23,"is_preprint":false},{"pmid":"37171262","id":"PMC_37171262","title":"ETS2 promotes cardiomyocyte apoptosis and autophagy in heart failure by regulating lncRNA TUG1/miR-129-5p/ATG7 axis.","date":"2023","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/37171262","citation_count":22,"is_preprint":false},{"pmid":"20569982","id":"PMC_20569982","title":"New insights for Ets2 function in trophoblast using lentivirus-mediated gene knockdown in trophoblast stem cells.","date":"2010","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/20569982","citation_count":22,"is_preprint":false},{"pmid":"25446535","id":"PMC_25446535","title":"Elf5 and Ets2 maintain the mouse extraembryonic ectoderm in a dosage dependent synergistic manner.","date":"2014","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/25446535","citation_count":21,"is_preprint":false},{"pmid":"36609474","id":"PMC_36609474","title":"A distal super-enhancer activates oncogenic ETS2 via recruiting MECOM in inflammatory bowel disease and colorectal cancer.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36609474","citation_count":21,"is_preprint":false},{"pmid":"24968297","id":"PMC_24968297","title":"MicroRNA 17-92 cluster mediates ETS1 and ETS2-dependent RAS-oncogenic transformation.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24968297","citation_count":21,"is_preprint":false},{"pmid":"27195074","id":"PMC_27195074","title":"The C-ETS2-TFEB Axis Promotes Neuron Survival under Oxidative Stress by Regulating Lysosome Activity.","date":"2016","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/27195074","citation_count":21,"is_preprint":false},{"pmid":"11771756","id":"PMC_11771756","title":"Beta-amyloid precursor protein, ETS-2 and collagen alpha 1 (VI) chain precursor, encoded on chromosome 21, are not overexpressed in fetal Down syndrome: further evidence against gene dosage effect.","date":"2001","source":"Journal of neural transmission. Supplementum","url":"https://pubmed.ncbi.nlm.nih.gov/11771756","citation_count":21,"is_preprint":false},{"pmid":"23542016","id":"PMC_23542016","title":"Hepatitis B virus core protein enhances human telomerase reverse transcriptase expression and hepatocellular carcinoma cell proliferation in a c-Ets2-dependent manner.","date":"2013","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23542016","citation_count":20,"is_preprint":false},{"pmid":"31754329","id":"PMC_31754329","title":"EGF suppresses the expression of miR-124a in pancreatic β cell lines via ETS2 activation through the MEK and PI3K signaling pathways.","date":"2019","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31754329","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50466,"output_tokens":9688,"usd":0.148359,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19937,"output_tokens":4633,"usd":0.107755,"stage2_stop_reason":"end_turn"},"total_usd":0.256114,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"Ras signaling induces phosphorylation of a conserved threonine residue (Thr-72) in ETS2, and mutation of this residue to alanine abrogates Ras-mediated superactivation of Ets-AP-1 reporter genes, establishing Thr-72 phosphorylation as a necessary molecular component of Ras-mediated ETS2 activation.\",\n      \"method\": \"Transient transfection reporter assays, site-directed mutagenesis, phosphoamino acid analysis of radiolabeled ETS2\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (mutagenesis, radiolabeling, phosphoamino acid analysis) in one rigorous study, replicated in subsequent papers\",\n      \"pmids\": [\"8552081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"MAP kinases p42 and p44 (ERK1/2) are the major ETS2 kinases downstream of CSF-1/c-fms signaling, phosphorylating ETS2 at Thr-72 in primary macrophages and fibroblasts; persistent ERK activation correlates with activation of the urokinase plasminogen activator (uPA) target gene.\",\n      \"method\": \"Phospho-specific antibody against pThr-72, immune depletion of MAP kinases, MEK inhibitor PD98059, in vitro kinase assays with recombinant ETS2, conditional raf kinase expression\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with recombinant substrate, immune depletion, pharmacological inhibition, and functional gene expression readout\",\n      \"pmids\": [\"9710599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"MAPK phosphorylation of ETS2 (and ETS1) at the conserved Thr-72 site results in enhanced transactivation through preferential, direct recruitment of the coactivators CBP and p300; both the phosphoacceptor site and the Pointed (PNT) domain are required for this interaction.\",\n      \"method\": \"Affinity chromatography screen of HeLa nuclear extracts using mock-treated vs ERK2-phosphorylated ETS proteins, binding assays with purified proteins, co-immunoprecipitation in vivo, reporter assays with MEK1 and CBP co-expression\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct binding with purified proteins, confirmed in vivo by co-IP, multiple orthogonal methods in one study\",\n      \"pmids\": [\"15572696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CDK10 interacts with the N-terminus (Pointed domain) of ETS2 and inhibits ETS2 transactivation activity; ETS2 requires an intact Pointed domain to bind CDK10, and CDK10 does not recognize ETS1 in a two-hybrid assay.\",\n      \"method\": \"Yeast two-hybrid assay, in vitro binding, co-immunoprecipitation in mammalian cells, reporter transactivation assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and in vitro binding, single lab, two orthogonal methods\",\n      \"pmids\": [\"11313931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CDK10 functions as a cyclin-dependent kinase activated by cyclin M (FAM58A product); CDK10/cyclin M phosphorylates ETS2 in vitro and positively controls ETS2 degradation by the proteasome, thereby negatively regulating ETS2 protein levels and downstream MAPK pathway activation.\",\n      \"method\": \"In vitro kinase assay, cyclin M co-expression/silencing, proteasome inhibitor experiments, analysis of STAR syndrome patient cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay, genetic validation in patient-derived cells, multiple orthogonal methods\",\n      \"pmids\": [\"24218572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Targeted deletion of the ETS2 DNA-binding domain causes defective trophoblast function; ETS2 is required for MMP-9 expression in trophoblasts and mediates FGF-induced MMP-3 and MMP-13 expression in fibroblasts; ectopic ETS2 rescues MMP expression in Ets2-deficient fibroblasts.\",\n      \"method\": \"Gene targeting/knockout mouse, tetraploid aggregation rescue, Northern blot/gene expression, ectopic expression rescue\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — targeted gene deletion with rescue experiment, multiple cell types, multiple target genes validated\",\n      \"pmids\": [\"9573048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Trophoblast stem cell self-renewal requires ETS2; conditional Ets2 inactivation decreases expression of Cdx2 (a direct Ets2 target) and other self-renewal genes while increasing differentiation-associated gene expression.\",\n      \"method\": \"Conditional gene targeting, gene expression analysis, chromatin immunoprecipitation identifying Cdx2 as a direct Ets2 target\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO, direct target validation by ChIP, multiple orthogonal methods\",\n      \"pmids\": [\"17977525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ETS2 is required in trophoblast for anteroposterior axis patterning of the embryo; Ets2 mutants show reduced extraembryonic ectoderm (EXE) markers, and physical removal of EXE phenocopies Ets2 mutant patterning defects, placing ETS2 downstream of FGF signals in EXE cells that relay patterning signals to the epiblast.\",\n      \"method\": \"Genetic knockout/epistasis, tetraploid aggregation, embryo culture/physical excision of EXE, gene expression analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with multiple rescue/phenocopy experiments, replicated observations\",\n      \"pmids\": [\"16481355\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ETS1 and ETS2 have essential and overlapping functions in endothelial cell survival during embryonic angiogenesis; double mutation of both factors causes embryonic lethality with vascular defects, loss of Mmp9, Bcl-XL, and cIAP2 expression, and increased endothelial apoptosis, with both factors loaded at target promoters.\",\n      \"method\": \"Conditional Cre/loxP knockout (endothelial-specific), chromatin immunoprecipitation, gene expression profiling of isolated embryonic endothelial cells, apoptosis assays in vivo and in vitro\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional cell-type-specific KO, ChIP confirming direct target occupancy, multiple orthogonal readouts\",\n      \"pmids\": [\"19411629\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ETS2 in tumor-associated macrophages (TAMs) drives a transcriptional program that represses anti-angiogenic gene inhibitors, promotes angiogenesis, and supports breast cancer lung metastasis; conditional Ets2 deletion in TAMs decreases metastasis frequency and tumor angiogenesis.\",\n      \"method\": \"Conditional knockout in macrophages (Cre/loxP), expression profiling, chromatin immunoprecipitation, multiple mouse mammary tumor models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional cell-type-specific KO, ChIP, three independent tumor models, multiple orthogonal readouts\",\n      \"pmids\": [\"20145133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Mutant p53 (gain-of-function) interacts with ETS2 to regulate gene expression through ETS-binding sites; this complex transactivates TDP2 (a DNA repair enzyme) to promote etoposide resistance in cancer cells.\",\n      \"method\": \"Genome-wide chromatin immunoprecipitation (ChIP), co-immunoprecipitation of mtp53 and ETS2, reporter assays, siRNA knockdown of TDP2\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, genome-wide ChIP with motif analysis, functional siRNA knockdown, multiple orthogonal methods\",\n      \"pmids\": [\"22508727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ETS2 in tumor fibroblasts promotes angiogenesis in breast cancer; conditional Ets2 deletion in stromal fibroblasts reduces tumor growth and vascularization, and ETS2 in fibroblasts directly promotes blood vessel formation in an in vivo angiogenesis assay independent of tumor cells.\",\n      \"method\": \"Conditional knockout in fibroblasts, gene expression profiling, in vivo angiogenesis assay, multiple PyMT and ErbB2 tumor models\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional cell-type-specific KO in two tumor models, in vivo angiogenesis assay, multiple orthogonal readouts\",\n      \"pmids\": [\"23977064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ETS2 suppresses MET proto-oncogene phosphorylation in non-small cell lung cancer cells; ETS2 knockdown activates the HGF/MET pathway and increases cell migration and invasion, while MET knockdown attenuates invasion induced by ETS2 siRNA, placing ETS2 upstream of MET as a tumor suppressor.\",\n      \"method\": \"siRNA knockdown, overexpression, pathway/microarray analysis, MET phosphorylation assays\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis by double knockdown, phosphorylation readout, single lab\",\n      \"pmids\": [\"23659968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ETS2 is a central regulator of human inflammatory macrophages; overexpressing ETS2 in resting macrophages reproduces the inflammatory state (including upregulation of TNF and IL-23) linked to chr21q22-associated inflammatory diseases, and ETS2 expression is amplified by a disease-associated intergenic haplotype on chr21q22.\",\n      \"method\": \"Functional genomics in primary human macrophages, ETS2 overexpression, gene expression profiling, identification of causal regulatory element, drug validation in vitro and ex vivo\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — gain-of-function in primary human cells, multiple orthogonal functional assays, rigorous regulatory genomics linking SNP to ETS2 expression\",\n      \"pmids\": [\"38839969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ETS2 is required for LPS-induced miR-155 expression in macrophages; ETS2 directly binds to the miR-155 promoter at an Ets-binding site proximal to the transcription start site, and ETS2-deficient mice display decreased LPS-induced miR-155; IL-10 inhibits ETS2 expression to suppress miR-155.\",\n      \"method\": \"Promoter deletion/mutation analysis, chromatin immunoprecipitation, Ets2-deficient mice, overexpression and knockdown\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo mouse genetics, ChIP, promoter mutagenesis, multiple orthogonal methods\",\n      \"pmids\": [\"24362029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HGF-MET signaling leads to accumulation of ETS2, which interacts with MLL (mixed lineage leukemia) histone methyltransferase to form a complex on MMP1 and MMP3 promoters; MLL trimethylates H3K4 at these promoters, activating transcription and promoting hepatocellular carcinoma invasion.\",\n      \"method\": \"Co-immunoprecipitation (ETS2-MLL complex), ChIP assays showing MLL-ETS2 occupancy and H3K4me3 at MMP1/MMP3 promoters, Mll-/-, Hgf-/-, Met-/- mouse phenotype comparisons\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, ChIP with histone modification readout, genetic validation across three mouse KO models\",\n      \"pmids\": [\"23934123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ETS2 phosphorylation at Thr-72 (by MAP kinase) is required for stromal support of mammary tumor progression; Ets2A72/A72 knock-in mice (Thr-72 → Ala) have reduced mammary tumor size and decreased MMP-9 and MMP-3 expression in macrophages, indicating that MAP kinase activation of ETS2 acts in the stroma to regulate protease expression.\",\n      \"method\": \"Knock-in mouse (Thr-72→Ala point mutation), tumor transplant, gene expression analysis in isolated macrophages, multiple transgenic tumor models\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — precise knock-in mutagenesis in vivo, multiple tumor models, cell-type-specific phenotype\",\n      \"pmids\": [\"14612405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Ets2 phosphorylation at Thr-72 mediates persistent inflammatory macrophage gene expression (TNF-α, CCL3, MMP-9, integrin αM, Bcl-X) in the motheaten viable model; the Ets2A72 allele reduces inflammation and macrophage survival in vivo, establishing that Thr-72 phosphorylation is required for Ets2's role in macrophage survival and inflammatory gene programs.\",\n      \"method\": \"Genetic combination of Ets2A72 knock-in allele with Hcph(me-v) mutation in mice, gene expression analysis in alveolar macrophages, apoptosis assays, LPS stimulation of bone marrow-derived macrophages\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic epistasis with knock-in allele, multiple target genes, functional phenotype\",\n      \"pmids\": [\"15240733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"In macrophages from motheaten-viable mice, ETS2 is phosphorylated at Thr-72 in a CSF-1/MAPK-independent manner; Akt immunoprecipitates catalyze Thr-72 phosphorylation of ETS2 in vitro, and the p54 JNK isoform co-immunoprecipitates with Akt and can act as an ETS2 kinase; PI3K inhibition reduces Ets-2 phosphorylation and Bcl-x expression.\",\n      \"method\": \"Phospho-specific Thr-72 antibody, Akt immunoprecipitate kinase assay with recombinant ETS2, co-immunoprecipitation of Akt and JNK, PI3K inhibitor (LY294002)\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with purified Akt immunoprecipitate, direct Co-IP, pharmacological validation, single lab\",\n      \"pmids\": [\"11027273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PTEN overexpression blocks insulin-stimulated ETS2 phosphorylation at Thr-72 by inhibiting ERK/MAP kinase activation (not via PI3K/Akt); this effect is phosphatase activity-dependent and abrogates ETS2-driven uPA Ras-responsive enhancer activity.\",\n      \"method\": \"Overexpression of wild-type and phosphatase-dead PTEN, MEK inhibitor (PD590089), PI3K inhibitor (LY492002), phospho-Thr-72 antibody, reporter assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection of pathway, functional reporter readout, multiple inhibitors, single lab\",\n      \"pmids\": [\"12095911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ETS2 is phosphorylated and activated by ERK1/2 in cardiomyocytes upon hypertrophic stimulation; ETS2 forms a complex with NFAT to bind promoters of hypertrophic genes (Rcan1.4, miR-223), linking ERK1/2 and calcineurin signaling; cardiomyocyte-specific ETS2 knockout protects mice from pressure overload-induced cardiac hypertrophy.\",\n      \"method\": \"Cardiomyocyte-specific conditional knockout mice, pressure overload model, calcineurin transgenic mouse silencing, ChIP for ETS2 and NFAT at target promoters, Co-IP of ETS2-NFAT complex, primary cardiomyocyte assays\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO in vivo, NFAT co-IP, ChIP, multiple orthogonal approaches in human and mouse samples\",\n      \"pmids\": [\"33821668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ETS2 overexpression induces apoptosis dependent on the p53 pathway; in ETS2 transgenic mice, increased apoptosis correlates with elevated p53 and downstream p53 pathway factors; crossing with p53-/- mice genetically rescues thymic apoptosis in ETS2 transgenic mice.\",\n      \"method\": \"ETS2 transgenic mice, p53 knockout cross, thymic apoptosis assay, transfection with functional p53 in HeLa cells\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis rescue experiment (ETS2 tg × p53-/-), multiple cell/tissue systems\",\n      \"pmids\": [\"12554679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ETS2 and PU.1 synergistically transactivate the bcl-x(L) promoter in macrophages; this synergy requires the transactivation domains of both proteins and is specific to ETS2 and PU.1 (not ETS1); ectopic co-expression of ETS2 and PU.1 increases macrophage survival upon CSF-1 withdrawal.\",\n      \"method\": \"Reporter transactivation assays, domain mapping/mutagenesis, overexpression in primary macrophages, cell survival assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reporter with domain mapping, overexpression in primary cells, single lab\",\n      \"pmids\": [\"11278399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ETS2 physically interacts with glucocorticoid receptor (GR) and synergistically transactivates the cytochrome P-450c27 promoter; GR binding to an adjacent cryptic GRE enables ETS2 to bind a weak Ets-like site; the GR DNA-binding domain alone (without transactivation domain) suffices for synergy, and the ETS2 transactivation domain is required.\",\n      \"method\": \"Co-immunoprecipitation, chemical cross-linking, transactivation assays with deletion mutants, reporter assays with GR-ETS2 fusion proteins\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and cross-linking confirming direct interaction, domain mapping, single lab\",\n      \"pmids\": [\"11279115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ETS2 interacts with the co-repressor ZMYND11 (BS69) through its N-terminus, resulting in weaker transcriptional activation compared to ETS1; this interaction allows ETS2 to compete for ETS1 binding sites and attenuate transcription, forming the molecular basis for ETS2's context-dependent tumor suppressive vs. oncogenic function.\",\n      \"method\": \"ETS1/ETS2 cistrome comparison (ChIP-seq), ETS1 deletion experiments, co-immunoprecipitation of ETS2-ZMYND11, reporter assays with N-terminal domain mutants\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq cistrome analysis, Co-IP, domain mapping, mechanistic model validated by multiple orthogonal methods\",\n      \"pmids\": [\"28119415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ETS2 transactivates the CD13/APN promoter via an Ets-core motif in endothelial cells; a phosphorylation-defective ETS2 T72A mutant fails to transactivate CD13/APN; siRNA knockdown of ETS2 inhibits CD13/APN transcription and prevents endothelial capillary network formation.\",\n      \"method\": \"Reporter assays with Ets-core motif mutations, Ets2 T72A phosphorylation-deficient mutant, siRNA knockdown, endothelial morphogenesis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — phosphorylation-defective mutant, siRNA knockdown, functional endothelial assay, multiple orthogonal methods\",\n      \"pmids\": [\"14507917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"ETS2 transactivates the human stromelysin (MMP-3) promoter via a proximal PEA-3 site; mutation of the proximal PEA-3 site significantly inhibits the TPA response, and ETS2 fails to transactivate promoters with mutated PEA-3 sites.\",\n      \"method\": \"Promoter deletion and point mutation analysis, co-transfection reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter mutagenesis plus transactivation assay, single lab, single main method\",\n      \"pmids\": [\"8463255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"ETS2 binds to ETS-binding site palindromes in the p53 promoter in gel-shift assays and activates p53 reporter expression 5–10-fold in COS cells; p53 mRNA levels are higher in NIH3T3 cells overexpressing ETS2, suggesting ETS2 is a transcriptional regulator of p53.\",\n      \"method\": \"Gel shift/EMSA assay with palindromic EBS oligonucleotides, CAT reporter co-transfection, Northern blot in ETS2-overexpressing cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct DNA binding assay plus reporter assay plus gene expression, single lab\",\n      \"pmids\": [\"8649821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ETS2 directly binds to EBS -93 in the HO-1 promoter (shown by gel shift) and transactivates HO-1 expression in macrophages; mutation of the ETS2 DNA-binding domain prevents HO-1 transactivation; dominant negative ETS2 blunts LPS-induced HO-1 expression.\",\n      \"method\": \"Promoter deletion analysis, gel shift/EMSA, DNA-binding domain mutation, dominant negative ETS2, reporter assays, kinase inhibitors\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct DNA binding confirmed by EMSA, domain mutagenesis, functional readout, single lab\",\n      \"pmids\": [\"15590657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ETS2 (and ETS1) directly bind to an Ets-binding site ~71–100 bp upstream of the miR-126 transcriptional start site and regulate miR-126 expression; knockdown of endogenous ETS1 and ETS2 decreases miR-126 expression in endothelial cells.\",\n      \"method\": \"Promoter mutation analysis, chromatin immunoprecipitation (ChIP), siRNA knockdown, reporter assays\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming occupancy, promoter mutagenesis, knockdown validation, single lab\",\n      \"pmids\": [\"20671229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ETS2 activates MKP3/DUSP6 transcription downstream of ERK1/2 activation in MCF-7 breast cancer cells; ETS2-dependent MKP3/DUSP6 induction provides a negative feedback on ERK1/2 activity and shifts the proliferation/growth arrest decision.\",\n      \"method\": \"Reporter assays, knockdown, ETS2 overexpression, ERK1/2 activity measurements, MKP3 induction analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct transcriptional regulation confirmed by reporter and knockdown, single lab, functional cellular readout\",\n      \"pmids\": [\"20554528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ETS2 and MESP1 co-expression converts human dermal fibroblasts into cardiac progenitors (KDR+ cells); ETS2 alone drives cardiac mesoderm commitment in embryonic stem cells, but neither ETS2 nor MESP1 alone generates cardiac progenitors from fibroblasts de novo.\",\n      \"method\": \"Lentivirus-mediated forced expression, embryonic stem cell differentiation assays, Ca2+ transient measurements, sarcomere detection, cardiac transcription factor marker analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional cellular reprogramming with multiple lineage markers, single lab\",\n      \"pmids\": [\"22826236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ETS2 overexpression promotes megakaryocyte expansion from wild-type and Gata1-mutant fetal liver progenitors; overexpression of ETS2 facilitates expansion of CD41+ cells from Gata1s knockin progenitors and synergizes with Gata1 mutations to reduce more mature CD42+ fractions.\",\n      \"method\": \"Retroviral overexpression in murine fetal liver progenitors, flow cytometry, serial replating assays, JAK/STAT pathway analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — overexpression in primary progenitors with genetic background variation, functional colony assay, single lab\",\n      \"pmids\": [\"19168790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ETS2 in pancreatic stromal fibroblasts directly binds regulatory sequences of chemokine genes (Ccl3, Ccl4, Cxcl4, Cxcl5, Cxcl10) and regulates immune cell recruitment; conditional Ets2 deletion in fibroblasts increases CD8+ T cells and decreases Tregs and myeloid-derived suppressor cells during acinar-to-ductal metaplasia.\",\n      \"method\": \"Conditional Ets2 knockout in fibroblasts, ChIP on chemokine promoters, immune cell flow cytometry in pancreatic ADM model\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional cell-type-specific KO, direct ChIP binding at multiple chemokine loci, functional immune phenotype\",\n      \"pmids\": [\"27659014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ETS2 directly binds the IL-6 promoter and inhibits IL-6 transcription; ETS2 also suppresses ERK1/2, JNK, p38, and p65 activation downstream of LPS and VSV, functioning as a negative regulator of macrophage inflammatory responses.\",\n      \"method\": \"ChIP assay on IL-6 promoter, ETS2 knockout mice, siRNA knockdown, CLP-induced sepsis model, kinase activation assays (Western blot)\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming direct promoter binding, in vivo KO model, single lab\",\n      \"pmids\": [\"31785145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ETS2 transactivates the beta-APP (amyloid precursor protein) gene via specific ETS-binding sites in the beta-APP promoter and cooperates with AP1; ETS2 transgenic mouse brains and neuronal cultures display elevated beta-APP protein, increased presenilin-1, and increased beta-amyloid production.\",\n      \"method\": \"Reporter assays with EBS mutations, ETS2 transgenic mice, Western blot for APP/presenilin-1/beta-amyloid\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter plus in vivo transgenic validation, single lab\",\n      \"pmids\": [\"12890557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ETS2 and p53 mediate cAMP/PKA-induced MMP-2 expression and trophoblast invasion; antisense inhibition of ETS2 or p53 reduces MMP-2 mRNA, secretion, and invasiveness in forskolin-treated trophoblast cells; ETS2 binds to its consensus site in the MMP-2 promoter in response to forskolin.\",\n      \"method\": \"EMSA binding assay, Northern blot/RT-PCR, antisense transfection, zymography, transwell invasion assay\",\n      \"journal\": \"Reproductive biology and endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct DNA binding by EMSA, functional antisense knockdown, multiple readouts, single lab\",\n      \"pmids\": [\"19939245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"ETS2 transactivates the cdc2 gene promoter via specific ETS-binding sites; cells constitutively expressing ETS2 have increased cdc2 expression, elevated histone H1 kinase activity, and higher cyclin A (but not cyclin B1) levels, and can grow under low serum conditions.\",\n      \"method\": \"Reporter transactivation assays with EBS mutations, constitutive ETS2 expression in BALB/c3T3, kinase assays, Western blot for cyclins\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter with site mutation, gain-of-function with kinase assay readout, single lab\",\n      \"pmids\": [\"7867724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Constitutive ETS2 expression in M1D+ myeloblast cells is sufficient to drive macrophage differentiation; ETS2 directly activates junB transcription via Ets-binding sites in the junB promoter, as shown by reporter assays and dominant negative ETS2 inhibition.\",\n      \"method\": \"Stable ETS2 transfection, differentiation marker analysis, transient reporter assays with junB promoter EBS, dominant negative ETS2\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — stable transfection with direct junB promoter target validation by reporter + dominant negative, single lab\",\n      \"pmids\": [\"8943340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"EGF activates ETS2 via MEK and PI3K pathways, and phosphorylated ETS2 (Thr-72) suppresses miR-124a promoter activity in pancreatic beta cells; ETS2 binds conserved AGGAANA/TN motifs in three miR-124a promoters; ETS2 knockdown reduces and overexpression promotes insulin biosynthesis.\",\n      \"method\": \"Kinase inhibitors (MEK and PI3K), ETS2 phosphorylation analysis, reporter assays with promoter EBS mutations, ETS2 knockdown/overexpression, insulin secretion/biosynthesis assays\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter with mutagenesis, phosphorylation-specific readout, functional insulin biosynthesis assay, single lab\",\n      \"pmids\": [\"31754329\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ETS2 is a transcription factor that is activated downstream of Ras/MAPK signaling via phosphorylation of a conserved Thr-72 residue by ERK1/2 (and in some contexts by Akt/JNK), which recruits CBP/p300 coactivators and enhances transactivation of target genes including MMPs, Bcl-XL, CD13/APN, HO-1, miR-155, miR-126, cdc2, beta-APP, and IL-6; CDK10/cyclin M phosphorylates ETS2 to promote its proteasomal degradation; ETS2 forms functional complexes with NFAT (in cardiomyocytes), MLL (in HGF-MET signaling), glucocorticoid receptor, PU.1, and gain-of-function mutant p53; its context-dependent oncogenic vs. tumor-suppressive activity is governed in part by interaction with the co-repressor ZMYND11; ETS2 is essential for trophoblast stem cell self-renewal (via Cdx2), embryonic anteroposterior axis patterning, endothelial cell survival during angiogenesis, and macrophage inflammatory gene programs, with Thr-72 phosphorylation status being a critical regulatory node for all these functions.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ETS2 is a sequence-specific transcription factor that converts Ras/MAPK signaling into target-gene programs governing tissue remodeling, angiogenesis, cell survival, and inflammation [#0, #5]. Its central regulatory event is phosphorylation of the conserved Thr-72 residue: ERK1/2 (p42/p44) are the principal ETS2 kinases downstream of growth-factor and CSF-1 signaling [#1], and in selected contexts Akt and the p54 JNK isoform also catalyze Thr-72 phosphorylation [#18]. Phosphorylated Thr-72, together with the Pointed (PNT) domain, recruits the coactivators CBP and p300 to drive transactivation [#2], whereas Thr-72-to-Ala knock-in mice lose stromal protease expression, macrophage survival, and inflammatory gene programs in vivo, establishing this residue as the obligate node for ETS2 output [#16, #17]. ETS2 binds Ets-core motifs at numerous promoters to control proteases (MMP-3, MMP-9, MMP-13), survival genes (Bcl-XL), CD13/APN, HO-1, miR-155, and miR-126, and is required for trophoblast stem-cell self-renewal through direct activation of Cdx2 and for embryonic anteroposterior axis patterning in extraembryonic ectoderm [#5, #6, #7, #8, #14, #25, #28]. ETS1 and ETS2 act redundantly to maintain endothelial survival during angiogenesis [#8], and stromal ETS2 in tumor-associated macrophages and fibroblasts promotes angiogenesis, immune-cell recruitment, and metastasis [#9, #11, #33]. ETS2 protein levels are limited by CDK10/cyclin M, which phosphorylates ETS2 and targets it for proteasomal degradation [#3, #4]. Context-dependent oncogenic versus tumor-suppressive behavior arises from partner choice: ETS2 cooperates with PU.1, the glucocorticoid receptor, NFAT, MLL, and gain-of-function mutant p53 in activating contexts [#10, #15, #20, #22, #23], but its N-terminal interaction with the co-repressor ZMYND11 weakens activation relative to ETS1 and lets ETS2 attenuate transcription by competing for shared Ets sites [#24]. In human macrophages ETS2 is a master driver of the inflammatory state, with a chr21q22 disease-associated haplotype amplifying ETS2 expression [#13].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established that Ras signaling acts on ETS2 through a single phosphorylation event, defining Thr-72 as the molecular switch for Ras-mediated activation.\",\n      \"evidence\": \"Reporter assays, site-directed mutagenesis (T72A), and phosphoamino acid analysis of radiolabeled ETS2\",\n      \"pmids\": [\"8552081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the physiological kinase\", \"Did not define how phosphorylation alters transactivation mechanistically\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified ERK1/2 as the major physiological ETS2 kinases downstream of CSF-1, connecting receptor signaling to Thr-72 phosphorylation and target-gene induction.\",\n      \"evidence\": \"Phospho-Thr-72 antibody, MAP kinase immune depletion, MEK inhibitor, in vitro kinase assays with recombinant ETS2 in macrophages and fibroblasts\",\n      \"pmids\": [\"9710599\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve coactivator recruitment\", \"Other kinase inputs not excluded\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Showed Thr-72 can be phosphorylated independently of CSF-1/MAPK via Akt and p54 JNK, broadening the signaling inputs converging on ETS2.\",\n      \"evidence\": \"Akt and JNK immunoprecipitate kinase assays, Co-IP, PI3K inhibitor, in motheaten-viable macrophages\",\n      \"pmids\": [\"11027273\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct kinase identity within the immunoprecipitate not fully purified\", \"Relative contribution of Akt vs JNK unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined the Pointed domain as a docking site for CDK10, providing the first negative regulator of ETS2 transactivation.\",\n      \"evidence\": \"Yeast two-hybrid, in vitro binding, reciprocal Co-IP, reporter assays\",\n      \"pmids\": [\"11313931\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Kinase activity of CDK10 toward ETS2 not yet shown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated combinatorial control of survival genes by showing ETS2 synergizes with PU.1 and with the glucocorticoid receptor to activate distinct promoters.\",\n      \"evidence\": \"Reporter transactivation, domain mapping, Co-IP/cross-linking, macrophage survival assays\",\n      \"pmids\": [\"11278399\", \"11279115\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous complex stoichiometry not defined\", \"Single lab for each interaction\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Proved in vivo that Thr-72 phosphorylation is required for ETS2's stromal and survival functions using a precise knock-in mutant.\",\n      \"evidence\": \"Ets2 T72A knock-in mice, tumor transplant, macrophage gene expression, motheaten-viable epistasis\",\n      \"pmids\": [\"14612405\", \"15240733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not separate which downstream kinase phosphorylates Thr-72 in each tissue\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Placed ETS2 within the apoptotic/tumor-suppressive axis by showing its overexpression triggers p53-dependent apoptosis.\",\n      \"evidence\": \"ETS2 transgenic mice crossed to p53-/-, thymic apoptosis assays\",\n      \"pmids\": [\"12554679\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which ETS2 elevates p53 not fully resolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Resolved the mechanistic basis of Thr-72 phosphorylation by showing it drives preferential recruitment of CBP/p300 coactivators, requiring both the phosphosite and the PNT domain.\",\n      \"evidence\": \"Affinity chromatography of nuclear extracts, purified-protein binding, in vivo Co-IP, reporter assays\",\n      \"pmids\": [\"15572696\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of phospho-dependent coactivator binding not solved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Mapped direct ETS2 target promoters across diverse genes, defining its Ets-core DNA-binding repertoire (CD13/APN, HO-1, MMP-3, p53, junB, cdc2, beta-APP).\",\n      \"evidence\": \"EMSA, promoter mutagenesis, reporter assays, dominant-negative and siRNA across multiple studies\",\n      \"pmids\": [\"14507917\", \"15590657\", \"8463255\", \"8649821\", \"8943340\", \"7867724\", \"12890557\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Several targets validated in single labs\", \"In vivo occupancy not confirmed for all\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Established essential developmental and vascular roles, including redundancy with ETS1 in endothelial survival and direct activation of self-renewal/angiogenic targets.\",\n      \"evidence\": \"Endothelial- and trophoblast-specific conditional knockouts, ChIP, gene expression profiling, apoptosis assays\",\n      \"pmids\": [\"19411629\", \"17977525\", \"16481355\", \"9573048\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degree of ETS1/ETS2 functional overlap across tissues not fully mapped\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined the CDK10/cyclin M kinase complex as the degradation-promoting regulator that sets ETS2 protein levels and dampens MAPK output.\",\n      \"evidence\": \"In vitro kinase assays, cyclin M silencing, proteasome inhibition, STAR syndrome patient cells\",\n      \"pmids\": [\"24218572\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase recognizing phosphorylated ETS2 not identified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed stromal and tumor-cell-context functions, including MLL-dependent H3K4me3 deposition at MMP promoters and dual oncogenic vs tumor-suppressive roles via MET.\",\n      \"evidence\": \"Co-IP, ChIP with histone-mark readout, conditional fibroblast KO, siRNA epistasis in lung and hepatocellular cancer models\",\n      \"pmids\": [\"23934123\", \"23977064\", \"23659968\", \"20145133\", \"22508727\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contextual determinants of oncogenic vs suppressive output not unified\", \"MET-suppression mechanism characterized in single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Provided a molecular explanation for ETS2's context-dependent dual function through its N-terminal ZMYND11 co-repressor interaction and competition with ETS1.\",\n      \"evidence\": \"ETS1/ETS2 ChIP-seq cistrome comparison, Co-IP, N-terminal domain mutants, reporter assays\",\n      \"pmids\": [\"28119415\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How signaling modulates the ETS2-ZMYND11 balance in vivo not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected ERK1/2 and calcineurin signaling in the heart by showing ETS2-NFAT complexes drive hypertrophic gene expression.\",\n      \"evidence\": \"Cardiomyocyte-specific KO, pressure overload model, ChIP, ETS2-NFAT Co-IP\",\n      \"pmids\": [\"33821668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NFAT partnership extends to non-cardiac contexts unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established ETS2 as a master driver of human inflammatory macrophages and linked its dysregulation to a chr21q22 disease haplotype.\",\n      \"evidence\": \"Functional genomics in primary human macrophages, ETS2 overexpression, causal regulatory element mapping, drug validation\",\n      \"pmids\": [\"38839969\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full set of downstream effector genes in human disease not enumerated\", \"Therapeutic targeting validated only in vitro/ex vivo\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how a single transcription factor integrates competing activating partners (CBP/p300, PU.1, NFAT, MLL, mutant p53) versus repressive interactions (ZMYND11) to produce cell-type-specific oncogenic, tumor-suppressive, developmental, or inflammatory outcomes.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural model of phospho-dependent partner selection\", \"E3 ligase for CDK10-primed degradation unidentified\", \"Determinants of ETS1 vs ETS2 site choice in shared cistromes unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 5, 24, 26]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [27, 28, 29, 36, 37]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [5, 8, 14, 24]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [13, 14, 17, 33]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CBP\", \"EP300\", \"CDK10\", \"ZMYND11\", \"NFAT\", \"MLL\", \"PU.1\", \"TP53\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}